Vemurafenib, a BRAF inhibitor, has shown promise in the treatment of patients with metastatic melanoma, non‐small cell lung cancer, papillary thyroid carcinoma, hairy cell leukemia, and Langerhans cell histiocytosis.31, 32, 33, 34, 35. The gene discussed is BRAF; the disease is differentiated thyroid carcinoma.